3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Myelodysplastic Syndromes
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Interventions
fludarabine
19
Cyclophosphamide
19
fludarabine phosphate
16
Azacitidine
14
Tacrolimus
13
Melphalan
13
venetoclax
10
Cytarabine
10
Busulfan
10
Whole-Body Irradiation
9
Thiotepa
9
Mycophenolic Acid
9
Stem Cell Transplantation
7
Peripheral Blood Stem Cell Transplantation
7
Decitabine
7
decitabine and cedazuridine drug combination
6
Methotrexate
6
Granulocyte Colony-Stimulating Factor
6
Specimen Handling
5
Sirolimus
5
CPX-351
5
AP 1903 reagent
5
thymoglobulin
4
Vorinostat
4
Mesna
4
Injections
4
Daunorubicin
4
Biopsy
4
Ipilimumab
3
Filgrastim
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Myelodysplastic Syndromes
×
bexmarilimab
×
Clear all
NCT05428969
2026-04-23
BEXMAB
Faron Pharmaceuticals Ltd
Phase 1/2
Active not recruiting
181 enrolled